Addex Therapeutics Ltd-Product Pipeline Review-2015

Addex Therapeutics Ltd-Product Pipeline Review-2015

  • Products Id :- GMDHC07257CDB
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Addex Therapeutics Ltd-Product Pipeline Review-2015


Global Markets Direct's, 'Addex Therapeutics Ltd-Product Pipeline Review-2015', provides an overview of the Addex Therapeutics Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Addex Therapeutics Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Addex Therapeutics Ltd including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Addex Therapeutics Ltd's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Addex Therapeutics Ltd's pipeline products

Reasons To Buy

Evaluate Addex Therapeutics Ltd's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Addex Therapeutics Ltd in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Addex Therapeutics Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Addex Therapeutics Ltd and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Addex Therapeutics Ltd

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Addex Therapeutics Ltd and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Addex Therapeutics Ltd Snapshot 6

Addex Therapeutics Ltd Overview 6

Key Information 6

Key Facts 6

Addex Therapeutics Ltd-Research and Development Overview 7

Key Therapeutic Areas 7

Addex Therapeutics Ltd-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Addex Therapeutics Ltd-Pipeline Products Glance 15

Addex Therapeutics Ltd-Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Addex Therapeutics Ltd-Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Addex Therapeutics Ltd-Drug Profiles 19

dipraglurant IR 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

dipraglurant ER 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ADX-68692 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ADX-71441 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ADX-71743 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ADX-88178 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

ADX-92639 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecule to Inhibit FSHR/LHR For Sex Hormone Dependent Tumors 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ADX-85142 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ADX-90125 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ADX-94819 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ADX-95477 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecule to Antagonize FSH Receptor for Women's Health 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecules to Agonize TRKB for Alzheimer's Disease 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Addex Therapeutics Ltd-Pipeline Analysis 37

Addex Therapeutics Ltd-Pipeline Products by Target 37

Addex Therapeutics Ltd-Pipeline Products by Route of Administration 38

Addex Therapeutics Ltd-Pipeline Products by Molecule Type 39

Addex Therapeutics Ltd-Pipeline Products by Mechanism of Action 40

Addex Therapeutics Ltd-Recent Pipeline Updates 41

Addex Therapeutics Ltd-Dormant Projects 47

Addex Therapeutics Ltd-Discontinued Pipeline Products 48

Discontinued Pipeline Product Profiles 48

ADX-10059 48

ADX-10061 48

ADX-71943 48

Addex Therapeutics Ltd-Company Statement 49

Addex Therapeutics Ltd-Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

Addex Therapeutics Ltd, Key Information 6

Addex Therapeutics Ltd, Key Facts 6

Addex Therapeutics Ltd-Pipeline by Indication, 2015 8

Addex Therapeutics Ltd-Pipeline by Stage of Development, 2015 11

Addex Therapeutics Ltd-Monotherapy Products in Pipeline, 2015 12

Addex Therapeutics Ltd-Out-Licensed Products in Pipeline, 2015 13

Addex Therapeutics Ltd-Out-Licensed Products/ Combination Treatment Modalities, 2015 14

Addex Therapeutics Ltd-Phase II, 2015 15

Addex Therapeutics Ltd-Phase I, 2015 16

Addex Therapeutics Ltd-Preclinical, 2015 17

Addex Therapeutics Ltd-Discovery, 2015 18

Addex Therapeutics Ltd-Pipeline by Target, 2015 37

Addex Therapeutics Ltd-Pipeline by Route of Administration, 2015 38

Addex Therapeutics Ltd-Pipeline by Molecule Type, 2015 39

Addex Therapeutics Ltd-Pipeline Products by Mechanism of Action, 2015 40

Addex Therapeutics Ltd-Recent Pipeline Updates, 2015 41

Addex Therapeutics Ltd-Dormant Developmental Projects,2015 47

Addex Therapeutics Ltd-Discontinued Pipeline Products, 2015 48

Addex Therapeutics Ltd, Subsidiaries 51

List of Figures

Addex Therapeutics Ltd-Pipeline by Top 10 Indication, 2015 8

Addex Therapeutics Ltd-Pipeline by Stage of Development, 2015 11

Addex Therapeutics Ltd-Monotherapy Products in Pipeline, 2015 12

Addex Therapeutics Ltd-Pipeline by Top 10 Target, 2015 37

Addex Therapeutics Ltd-Pipeline by Top 10 Route of Administration, 2015 38

Addex Therapeutics Ltd-Pipeline by Top 10 Molecule Type, 2015 39

Addex Therapeutics Ltd-Pipeline Products by Top 10 Mechanism of Action, 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Addex Therapeutics Ltd; Addex Therapeutics Ltd - Key Therapeutics; Addex Therapeutics Ltd - Pipeline Overview and Promising Molecules; Addex Therapeutics Ltd - News; Addex Therapeutics Ltd - Latest Updates; Addex Therapeutics Ltd - Pipeline; Addex Therapeutics Ltd - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 107820
Site License
USD 3000 INR 215640
Corporate User License
USD 4500 INR 323460



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]